RUNX1 and acute myeloid leukemia: Chromatin spliceosome mutations in AML, like ASXL1, BCOR, RUNX1, and STAG2, demonstrate inferior clinical outcomes similar to other adverse risk AML, with a high rate of relapse and poor long-term survival.